Signaturefd LLC grew its position in Becton Dickinson and Co (NYSE:BDX) by 11.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,992 shares of the medical instruments supplier’s stock after acquiring an additional 207 shares during the period. Signaturefd LLC’s holdings in Becton Dickinson and were worth $504,000 at the end of the most recent quarter.
Other hedge funds also recently added to or reduced their stakes in the company. Eagle Asset Management Inc. purchased a new stake in shares of Becton Dickinson and during the second quarter worth about $2,062,000. GAM Holding AG increased its stake in shares of Becton Dickinson and by 56.4% during the second quarter. GAM Holding AG now owns 48,870 shares of the medical instruments supplier’s stock worth $12,316,000 after purchasing an additional 17,622 shares in the last quarter. CIBC Asset Management Inc increased its stake in shares of Becton Dickinson and by 0.5% during the second quarter. CIBC Asset Management Inc now owns 53,480 shares of the medical instruments supplier’s stock worth $13,477,000 after purchasing an additional 247 shares in the last quarter. Black Diamond Financial LLC purchased a new stake in shares of Becton Dickinson and during the second quarter worth about $562,000. Finally, Findlay Park Partners LLP increased its stake in shares of Becton Dickinson and by 8.3% during the second quarter. Findlay Park Partners LLP now owns 2,220,000 shares of the medical instruments supplier’s stock worth $559,462,000 after purchasing an additional 170,000 shares in the last quarter. 84.23% of the stock is owned by institutional investors and hedge funds.
In other news, Director Claire Fraser sold 1,429 shares of the stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $243.26, for a total value of $347,618.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Vincent A. Forlenza sold 11,532 shares of the stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $260.38, for a total transaction of $3,002,702.16. Following the completion of the sale, the chief executive officer now directly owns 218,671 shares of the company’s stock, valued at approximately $56,937,554.98. The disclosure for this sale can be found here. In the last three months, insiders sold 37,249 shares of company stock valued at $9,616,803. Corporate insiders own 0.12% of the company’s stock.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share for the quarter, beating the consensus estimate of $3.05 by $0.03. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The business had revenue of $4.35 billion during the quarter, compared to analysts’ expectations of $4.37 billion. During the same quarter in the prior year, the company posted $2.91 EPS. The business’s revenue for the quarter was up 1.7% on a year-over-year basis. Equities research analysts predict that Becton Dickinson and Co will post 11.68 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Monday, September 30th. Stockholders of record on Monday, September 9th were paid a $0.77 dividend. The ex-dividend date of this dividend was Friday, September 6th. This represents a $3.08 annualized dividend and a dividend yield of 1.19%. Becton Dickinson and’s dividend payout ratio (DPR) is 27.97%.
A number of research firms have recently commented on BDX. Wells Fargo & Co boosted their target price on shares of Becton Dickinson and from $270.00 to $290.00 and gave the stock an “outperform” rating in a research note on Friday, September 6th. ValuEngine cut shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Morgan Stanley upped their price objective on shares of Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 16th. Piper Jaffray Companies dropped their price objective on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Finally, Raymond James upped their price objective on shares of Becton Dickinson and from $265.00 to $288.00 and gave the company a “strong-buy” rating in a research note on Friday, June 28th. Five investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Becton Dickinson and has an average rating of “Buy” and an average target price of $266.55.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Story: Trading Ex-Dividend Strategy
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.